前列腺癌新辅助内分泌治疗

前列腺癌新辅助内分泌治疗新辅助内分泌治疗(eaduathrneNHT或ntadoe-piainnADT内分治疗9年Mone报切除术前的辅助治疗,结果显示前列腺体积及肿瘤体积明显减小,术中失血减少,手术时间缩短,发本在%的T0近0治是的直。列预前体A水平及Gleasn。助疗腺治除前6月T前平小2（1而（3NHT能有效降浆PA（要等PA5为T能够床2列腺癌分期，床T3期肿瘤NHT现即临断时的分期过所致6，7。缘可加列癌局复、处移死率与切NHT能显著降低临床T2期及以下前列腺癌的切缘阳性，8床T3期（0原因能是NHT导致前列，不阳此T却的esn但究可种。么T治疗能否床3行T治？腺组在20年道了2例T2-00期癌患随果中T有2例患者予3个雄阻断治疗（戈+氟访4年。结果显示管NHT组(纯术组)atlgialowsai15%v7%,p<0.0床T2是T3（c2p00;3,001化义(P=0.18)对床T2分时,HT高(3/102s,=),床3组统义(7s21/95,p=0.)示NHT治床T2对3（1。6，Hsu等报道235例临床T3a期（2中NHT组5例组0的5床P（prgesnfesurvia分别为43.和77.6%后者的别为59.5%和95.前者的肿瘤特异生存cuv,CSS）和总体率(llsvl,OS)分别为88.7%和79.8为98.%和95.9%为33.和57.1明T疗和照组(纯组)间5CS:p=.2;O:p=.1r等对176例临床T3为NHT益疾。.LupronDepotNeoadjuvantProstateCancerGroup多中心前瞻性随对床Tb期前列腺现NHT组（3+氟5生<与照无显差68%s676,p=0.663。（13）1年r756中0例受了T疗,为8月比间有,现NT过3者低化,Gee等(14)者NHT治疗8,手疗访5年其较。2年瑞典的随机对照研究中5，6例局限性癌中NHT和纯手术各半以T2a期治切缘阳性率差异显著，分别为45.5和23.6%（p=0.016。但是无生化进展生存率（PSA<0.5ng/m与无差分为49.8和51.5%（p08。在最（16有2474列腺癌中NHT组1083例，单纯近距离放射组1391间48随（73T和的aaemoratACM（p4≥3岁中T的ACM加调危比14，9区间1013，1。究助者年3，以及可逆性的认知障碍等，而且新辅助内分泌治疗对生存期改善不明显，尤其是对于临床T3床2，随着新辅助治疗时间延长至超过3个。献u,gXH,u,etal.Compraivesyoftheimpactof32versus82mothnoajvathomnlyonoeoflpaocpcraial.JCancersClnOncl,207,133(8:555-562.2.Hsu,JoniauS.CoprgreslsafersyinpatetswhclilunilterlT3aprostatecancertreatedwithorwithoutneoadjuvantandrogen-deprivationtherapy.BJUInt,2006,9):11-..BrnsdtS,chC,HmM,etal.N-tnHthayadlprostatectomy:effectsontumorousandbenigntissuevolumes-amorphometricstudy.UrolRes,197,25(1:43-47.4.GlaeME,GolenegSL,JonsEC,etal.Bicemclandpatooiclefetsof8motsofnoutanroenwiraltrybeforeraialyinpatintswhcilyoidpoaeae.Jrl,9,551:13-1.5.LodG,hsnC,Kin,et.SAelsdteaefpiesgalrnsnrdclpyscnsprcdedyanroenbeinclialB(bxo)pottecacr.TheLupronDepotNeoadjuvantStudyGroup.Urology,1997,49(3ASuppl):70-73.6.TunnUW.Neo-adjuvanthormonaltherapyofprostatecancer.UrolRes,1997,25Suppl2:S57-S6.7.LabrieF,DupontA,CusanL,etal.Downstagingoflocalizedprostatecancerbyneoadjuvantywithfltmieandlupon:theftctldadrdta.ClinInstM,193,16(6):499-50.8.Mr,BaitiI,BédardC,etal.Durationofneodjvntanrgendpvintheraybeforerdclpratyaddisease2freesurialinnwithprsate.,201,58(2Suppl1):71-77.9.DebruyneFM,WitjesWP.Neoadjuvanthormonaltherapypriortoradicalprostatectomy:theEuoenexpeine.MolUrl,200,4(3):251-25;disuson25710.PetrakiCD,SfikasCP.Histopathologicalchangesinducedbytherapiesinthebenignprostateadprotteaencriom.HisolHsopto,207,22(1:107–8.SnCC,Derye,Fr,etal.rfolo-upresultsofaErenprospectiverandomizedstudyonneoadjuvanthormonaltherapypriortoradicalprostatectomyinT2-3N0M0prostatecancer.EuropeanStudyGrouponNeoadjuvantTreatmentofProstateCancer.EurUro,2000,38(6):706-713.12.CavrBS,BinoJJ,Scardino,eta.Lmoutcmefollwingrdclpsemynmnwthnalge3pstenr.Jo,0,162:6581.y,Pareek,ShrfiR,etal.NetandrgnabltonbferaialprostatectomyincT2bNxM0prostatecancer:5-yearresults.LupronDepotNeoadjuvantProstatearyu.J,0,7,6.14.GleaveME,LaBiancaSE,GoldenbergSL,etal.Long-termneoadjuvanthormonetherapypriortoradicalprostatectomy:evaluationofriskforbiochemicalrecurrenceat5-yearfollow-up.,,6:9–.15.AbrahamssonGP,Ahlgren,HugossonJ,etal.Three-monthneoadjuvanthormonetherapybeforeradicalprostatectomy:a7-yearfollow-upofarandomizedcontrolledtrail.BJUInt,2002,90,561-5